Lurbinectedin is a chemotherapy drug that has shown promising results in the treatment of various cancers, including small cell lung cancer (SCLC) [1]. Immunotherapy, on the other hand, is a type of cancer treatment that uses the body's immune system to fight cancer cells [2].

Combining lurbinectedin with immunotherapy, specifically pembrolizumab, has shown promising preliminary results in the treatment of relapsed SCLC [3]. However, there is limited information on the adverse effects of combining lurbinectedin with immunotherapy.

A study published in the Journal of Clinical Oncology reported that combining lurbinectedin with pembrolizumab did not result in any significant increase in adverse events [2]. However, it is important to note that this study had a small sample size and further research is needed to fully understand the potential adverse effects of combining these two treatments.

In conclusion, while there is limited information on the adverse effects of combining lurbinectedin with immunotherapy, preliminary results suggest that there may not be a significant increase in adverse events. However, further research is needed to fully understand the potential risks and benefits of combining these treatments.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469650/
[3] https://www.cancernetwork.com/view/antonio-calles-md-highlights-promising-preliminary-activity-of-lurbinectedin-and-pembrolizumab-in-relapsed-sclc